Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.86 |
| ▸ | SPR | P35270 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | IDO1 | P14902 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 5/20 | 0.65 |
| ▸ | HTR2A | P28223 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471374 | 1.00 | HTR2C (1.00) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| Oxalic Acid SCHEMBL1320479 | 0.93 | KDM4E (1.00) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL29693558 | 0.90 | HTR2C (0.81) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| Maleic Acid SCHEMBL6271093 | 0.89 | NPSR1 (0.83) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| Fumaric Acid SCHEMBL6271100 | 0.89 | NPSR1 (0.83) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL12352656 | 0.88 | HTR2C (0.78) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL27788551 | 0.86 | HTR2C (0.75) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL15920450 | 0.85 | HTR2C (0.74) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL14297488 | 0.84 | HTR2C (0.73) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL2316403 | 0.84 | HTR2C (0.73) | HTR2CKDM4ECYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| US-20250345370-A1 | MICROBIAL LIBERATION OF N-METHYLSEROTONIN FROM ORANGE FIBER | WASHINGTON UNIVERSITY (US) | 2025-11-13 | — | — | US | claimed |
| CN-120019812-A | Artificial toad venom composition and application thereof | 南京中医药大学 | 2025-05-20 | — | — | CN | claimed |
| CN-118702610-A | Separation and purification method of indole alkaloid monomer compounds in venenum bufonis medicinal materials | 宝鸡文理学院 | 2024-09-27 | — | — | CN | claimed |
| WO-2023201326-A1 | MICROBIAL LIBERATION OF N-METHYLSEROTONIN FROM ORANGE FIBER | WASHINGTON UNIVERSITY (US) | 2023-10-19 | — | — | WO | claimed |
| CN-116814668-A | Biosynthesis method of N-methyl serotonin and N-N-dimethyl serotonin | 福建师范大学 | 2023-09-29 | — | — | CN | claimed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | claimed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | claimed |
| EP-3989992-A2 | THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS | Holobiome, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| US-20140213536-A1 | MARKETING N-METHYLSEROTONIN AND RELATED SUBSTANCES FOR USE IN TREATING/ LESSENING THE OCCURRENCE OF HOT FLASHES RELATED TO MENOPAUSE | DSM IP ASSETS B.V. (NL) | 2014-07-31 | — | — | US | claimed |
| EP-2164500-B1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2013-12-04 | — | — | EP | claimed |
| US-20110300142-A1 | USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2011-12-08 | — | — | US | claimed |
| EP-2282993-A1 | PROCESS FOR PREPARING 3-INDOLYL FATTY ACID AMIDES WITH SATURATED, UNSATURATED OR HYDROXY FATTY ACIDS | Technische Universität Dresden (DE) | 2011-02-16 | — | — | EP | claimed |
| EP-2164500-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | Idogen AB (SE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009144175-A1 | PROCESS FOR PREPARING 3-INDOLYL FATTY ACID AMIDES WITH SATURATED, UNSATURATED OR HYDROXY FATTY ACIDS | Technische Universität Dresden (DE) | 2009-12-03 | — | — | WO | claimed |
| WO-2008147283-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | SALFORD LEIF (SE) | 2008-12-04 | — | — | WO | claimed |
| EP-1112106-B1 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON MFG LTD (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1112106-A2 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2001-07-04 | — | — | EP | claimed |
| WO-2000016761-A2 | SEROTONERGIC 5HT2 AGONISTS FOR TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 2000-03-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2C 6/4885KDM4E 1476/4885CYP2D6 1702/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | HTR2C 1076/4885KDM4E 3063/4885CYP2D6 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.